GIP-GLP-1-Glucagon agonist

Retatrutide: A Breakthrough Triple Agonist for Obesity and Type 2 Diabetes Management

Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profil